EDARAVONE

Product Description

is leading manufacturer and distributer of theEdaravoneamong the other countries. NiksanPharmaceutical is one of the major the supplier, distributer, exporter andmanufacturer of the EdaravoneAPI and finished formulations in Ankleshwar,Gujarat, India. The products of Niksan Pharmaceutical and Niksan groupcompanies are widely appreciated by the clients and other companies.

Niksan Pharmaceutical is the supplier,manufacturer, exporter and trader of Edaravonein the domestic level as well as the internationalmarket. 

 

Niksan Pharmaceutical provides EdaravoneAPI in all over Indian states like Jammu & Kashmir,Himachal Pradesh, Uttarakhand, Punjab, Kerala, Chandigarh, Chhattisgarh, AndhraPradesh, Rajasthan, Meghalaya,Mizoram, Nagaland, Orissa,, Dadra and NagarHaveli, Goa, Gujarat,Jharkhand, West Bengal, Karnataka, Kerala, Madhya Pradesh etc.

 

Niksan Pharmaceutical also provides EdaravoneAPI andfinished formulations in all other countries of the world like Germany,Switzerland, Poland, Latvia, Egypt, Lithuania, Estonia, Ukraine, Moldova,Russia, United States, Austria, Belarus, Serbia, India, Spain, Slovenia,Nigeria, Croatia, South Africa, Kazakhstan, Italy, Romania, Bulgaria, Portugal,South Korea, Greece, Philippines, Belgium, Saudi Arabia, Turkey, Japan etc.

 

Edaravoneis one type of  medication . It maywork to slow the nerve damage associated with the worsening of ALS symptoms.

SYNONYMS: Edaravone, Methylphenylpyrazolone, Norphenazone, Phenyl methyl, pyrazolone,Phenylmethylpyrazolone

 

IUPAC NAME:5-methyl-2-phenyl-4H-pyrazol-3-one

 

CAS NO: 89-25-8

 

FORMULA:  C₁₀H₁₀N₂O

 

MOLECULAR MASS: 174.203 g/mol

 

STORAGE OF EDARAVONE:Store at up to 25C (77F). Excursions permitted from 15C to 30C (59F to86F) [see USP Controlled Room Temperature]. Protect from light. Store inoverwrapped package to protect from oxygen degradation until time of use.

 

APPLICATIONS OF EDARAVONE:Edaravone injection is used to treat amyotrophic lateral sclerosis(ALS, Lou Gehrigs disease; a condition in which the nerves that control musclemovement slowly die, causing the muscles to shrink and weaken). Edaravone injection is in a class of medicationscalled antioxidants.

The recommended dose of edaravoneis 60 mg administeredvia 60-minute IV infusion once daily for 14 days as the initial treatmentcycle, followed by a 14-day drug-free period.Subsequent treatment cycles consist of once-daily dosing for 10 of 14 days,each followed by a 14-day drug-free period.

HOW EDARAVONE WORKS: The recommended dose of edaravoneis 60 mg administeredvia 60-minute IV infusion once daily for 14 days as the initial treatmentcycle, followed by a 14-day drug-free period.Subsequent treatment cycles consist of once-daily dosing for 10 of 14 days,each followed by a 14-day drug-free period.

CONTRAINDICATIONS OF EDARAVONE: Edaravoneis contraindicated for use in patients with a history of ahypersensitivity to edaravone or any of the inactive ingredients, includingsulfite hypersensitivity. Hypersensitivity reactions, including anaphylacticreactions, have occurred with edaravone.

PHARMACOKINETICS OF EDARAVONE: Edaravone is metabolized to a sulfate conjugate and a glucuronideconjugate, which are not pharmacologically active.The glucuronide conjugation of edaravone involves multiple uridine diphosphateglucuronosyltransferase (UGT) isoforms (UGT1A1, UGT1A6, UGT1A7, UGT1A8, UGT1A9,UGT1A10, UGT2B7, and UGT2B17).

 

SIDE EFFECTS OF EDARAVONE:  In some cases, Blistering, crusting, irritation, itching, or reddening of the skin,blue lips, fingernails, or skin, chest pain or tightness, change in walking andbalance, clumsiness or unsteadiness,cough, Confusion, racked, dry, scaly skin.

 

PRECAUTIONS: Talk to your nurse ordoctor right away if you have very fast or irregular breathing, a very fast orirregular heartbeat, a rash, fainting, hive-like swellings on the skin, orswelling of the eyelids or around the eyes, face, lips, or tongue.

 

CDSCO APPROVAL:

Edaravone injection are approved byCDSCO in India in 27.07.07

 

FORMULATION AVAILABLEIN MARKET:

Edaravone 1.5 MG injection

Edaravone 30MG/20ML injection

 

Note: Product protected by validpatents are not offered for sale in countries where such patents are stillvalid and its liability is at Buyers Risk

 

REFERENCES:

 

www.webmd.com

https://pubchem.ncbi.nlm.nih.gov

https://go.drugbank.com

https://cdscoonline.gov.in

https://www.wikipedia.org/

https://www.drugs.com

https://www.zaubacorp.com

https://www.practo.com/consult

Key Features and Composition

EDARAVONE stands out for its high purity (99%) and long shelf life of 3 years. The molecule is a white to off-white solid, with a melting point of 129.7C and a boiling point of 191C. Manufactured and supplied in India, it is available for both export and distribution. EDARAVONE is provided in powder form, with specific particle sizes to ensure optimal application in medical formulations.


Solubility and Storage Instructions

This compound is characterized by its solubility: freely soluble in acetic acid, methanol, and ethanol, but only slightly soluble in water and diethyl ether. For maximum efficacy and stability, EDARAVONE should be stored at room temperature, away from moisture and direct sunlight. The product maintains its properties when these guidelines are followed, supporting reliable long-term use.


Therapeutic Usage and Benefits

EDARAVONE serves as a therapeutic agent, particularly in managing ALS (Amyotrophic Lateral Sclerosis). By targeting and slowing nerve damage, this medication helps to mitigate the worsening of symptoms, offering meaningful clinical benefits to patients undergoing treatment. Its proven efficacy and consistency make it a trusted choice within pharmaceutical circles.